Skip to main content
Fig. 3 | Molecular Medicine

Fig. 3

From: Gene therapy of yeast NDI1 on mitochondrial complex I dysfunction in rotenone-induced Parkinson’s disease models in vitro and vivo

Fig. 3

The mitochondrial oxidative phosphorylation function in rotenone-induced PD cell model transduced with NDI1. A The mitochondrial complex I enzyme activity was determined by measuring the NADH oxidation rate using a spectrophotometer. B The basal oxygen consumption (Base), ATP synthase uncoupling oxygen consumption after oligomycin treatment (Oligo), and maximum oxygen consumption after FCCP treatment (FCCP) were detected using a cellular respiration apparatus. C RCRs (respiratory control rates) were calculated as Base /Oligo. D LCRs (leakage control rates) were calculated as Oligo/FCCP. E The basal ATP content (Base) and oligomycin-sensitive ATP content (Oligo-sensitive) were measured using a luciferin/luciferase chemiluminescence ATP assay kit. F The ratios of oligomycin-sensitive ATP content were calculated as Oligo-sensitive/ Base. Rotenone + vector group compared with DMSO + vector group, or Rotenone + NDI1 group compared with Rotenone + vector group, or Rotenone + NDI1 group compared with DMSO + vector group, ns not significant. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page

Molecular Medicine

ISSN: 1528-3658